Detalhe da pesquisa
1.
Emergency percutaneous nephrostomy versus emergency percutaneous nephrolithotomy in patients with sepsis associated with large uretero-pelvic junction stone impaction: a randomized controlled trial.
Int Braz J Urol
; 43(3): 481-488, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28128911
2.
Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers.
Bioconjug Chem
; 26(5): 919-31, 2015 May 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-25915780
3.
Trogocytosis of multiple B-cell surface markers by CD22 targeting with epratuzumab.
Blood
; 122(17): 3020-9, 2013 Oct 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-23821660
4.
Trop-2-targeting tetrakis-ranpirnase has potent antitumor activity against triple-negative breast cancer.
Mol Cancer
; 13: 53, 2014 Mar 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-24606732
5.
Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas.
Blood
; 119(16): 3767-78, 2012 Apr 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-22271448
6.
Predictive patient-specific dosimetry and individualized dosing of pretargeted radioimmunotherapy in patients with advanced colorectal cancer.
Eur J Nucl Med Mol Imaging
; 41(8): 1593-602, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-24643780
7.
Sacituzumab govitecan plus platinum-based chemotherapy mediates significant antitumor effects in triple-negative breast, urinary bladder, and small-cell lung carcinomas.
Oncotarget
; 15: 144-158, 2024 Feb 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-38386805
8.
Prevention of acute graft-versus-host disease in a xenogeneic SCID mouse model by the humanized anti-CD74 antagonistic antibody milatuzumab.
Biol Blood Marrow Transplant
; 19(1): 28-39, 2013 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-23025988
9.
Optimization of multivalent bispecific antibodies and immunocytokines with improved in vivo properties.
Bioconjug Chem
; 24(1): 63-71, 2013 Jan 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-23116517
10.
Preclinical studies on targeted delivery of multiple IFNα2b to HLA-DR in diverse hematologic cancers.
Blood
; 118(7): 1877-84, 2011 Aug 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-21680794
11.
Targeting both IGF-1R and mTOR synergistically inhibits growth of renal cell carcinoma in vitro.
BMC Cancer
; 13: 170, 2013 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-23548153
12.
Horizontal transmission and retention of malignancy, as well as functional human genes, after spontaneous fusion of human glioblastoma and hamster host cells in vivo.
Int J Cancer
; 131(1): 49-58, 2012 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-21796629
13.
The dock-and-lock method combines recombinant engineering with site-specific covalent conjugation to generate multifunctional structures.
Bioconjug Chem
; 23(3): 309-23, 2012 Mar 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-22168393
14.
Multiple signaling pathways induced by hexavalent, monospecific, anti-CD20 and hexavalent, bispecific, anti-CD20/CD22 humanized antibodies correlate with enhanced toxicity to B-cell lymphomas and leukemias.
Blood
; 116(17): 3258-67, 2010 Oct 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-20628151
15.
Therapy of B-cell malignancies by anti-HLA-DR humanized monoclonal antibody, IMMU-114, is mediated through hyperactivation of ERK and JNK MAP kinase signaling pathways.
Blood
; 115(25): 5180-90, 2010 Jun 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-20101022
16.
Pretargeting: taking an alternate route for localizing radionuclides.
Tumour Biol
; 33(3): 591-600, 2012 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-22396041
17.
Signal amplification in molecular imaging by pretargeting a multivalent, bispecific antibody.
Nat Med
; 11(11): 1250-5, 2005 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-16258537
18.
Low dose oral desmopressin for nocturnal polyuria in patients with benign prostatic hyperplasia: a double-blind, placebo controlled, randomized study.
J Urol
; 185(1): 219-23, 2011 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-21074790
19.
Hexavalent bispecific antibodies represent a new class of anticancer therapeutics: 1. Properties of anti-CD20/CD22 antibodies in lymphoma.
Blood
; 113(24): 6161-71, 2009 Jun 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-19372261
20.
CD20-targeted tetrameric interferon-alpha, a novel and potent immunocytokine for the therapy of B-cell lymphomas.
Blood
; 114(18): 3864-71, 2009 Oct 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-19710501